Pfizer Global Research & Development, France

France

1 December 2019 - 30 November 2020

No articles found. Pfizer Global Research & Development, France did not contribute to any primary research papers from Nature Index journals in the current 12 month window.

Pfizer Inc.

↳ Pfizer Global Research & Development, France

Anacor Pharmaceuticals, Inc.

Array BioPharma, Inc.

Cardiovascular and Metabolic Diseases Research Unit (CVMED RU), Pfizer

FoldRx Pharmaceuticals Inc.

Hospira Inc.

Hospira Zagreb d.o.o.

Medivation, Inc.

Neusentis UK

Neusentis US

Icagen, Inc.

Icagen-T Inc.

Pfizer Biotherapeutics R&D, Andover

Pfizer Canada Inc.

Pfizer Vaccines Research Unit

Pfizer Cancer Immunology Unit

Pfizer Drug Safety Research & Development, Andover

Pfizer Global Research & Development, Cambridge

Pfizer Global Research & Development, Sandwich

Pfizer Immunoscience Research Unit

Pfizer Inflammation and Immunology

Pfizer Ireland Pharmaceuticals

Pfizer Italia srl

Pfizer Ltd.

Pfizer Neuroscience and Pain Research Unit

Pfizer New Haven Clinical Research Unit (CRU)

Pfizer Pharmaceuticals Korea Limited

Pfizer Pharmacokinetics, Dynamics and Metabolism (PDM)

Pfizer R&D Andover, MA

Pfizer R&D Cambridge, MA

Pfizer R&D Groton, CT

Pfizer R&D La Jolla, CA

Pfizer R&D Pearl River, NY

Pfizer R&D Rinat, San Francisco, CA

Pfizer R&D St. Louis, MS

Pfizer Sweden

Pfizer Worldwide Research & Development (WRD)

Pfizer's Centers for Therapeutic Innovation (CTI), Boston

Pfizer's Centers for Therapeutic Innovation (CTI), San Francisco

Pfizer, S.L.

Pharmacia & Upjohn S.p.A

Rinat Neuroscience Corporation

Thiakis Limited

Wyeth

Return to institution outputs

Latest supplement

Nature Index 2020 Artificial Intelligence

Artificial intelligence is one of the most rapidly advancing and controversial topics in scientific research. As investments and revenues soar year-on-year and nations vie for leadership in the field, AI research output continues its steep, upward trajectory. But there are significant ethical and technical challenges to overcome.

Access free